1例肾细胞癌服用舒尼替尼患者的药学监护  

Pharmaceutical care for a renal cell carcinoma patient with administration of sunitinib

作　　者：李敏[1] 林晓贞 郑芝欣[1] 

机构地区：[1]河南省南阳市中心医院药学部 [2]郑州大学附属肿瘤医院药学部

出　　处：《中国临床药理学与治疗学》2016年第5期538-542,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:临床药师通过对1例肾细胞癌术后服用舒尼替尼患者的药学服务,为临床合理用药提供参考。方法:患者服用舒尼替尼出现高血压、皮肤黄染、纳差等药物不良反应,临床药师通过查阅文献,掌握舒尼替尼的药理作用、药代动力学、不良反应以及应采取的防范措施,参与患者的治疗过程,根据患者肾功能状态与临床医师共同制订合理的治疗方案,并对患者进行用药监护和干预。在对舒尼替尼用药剂量进行调整后,患者未再出现严重不良反应,胸腔积液处理和抗骨转移治疗过程顺利,患者耐受性与依从性好。结果:在临床药师积极的监护和干预下,患者药物不良反应得到控制,临床症状改善,配合临床医师顺利完成了本次治疗。结论:临床药师通过对患者的药学监护与干预,与临床医生协作,可以提高患者治疗依从性,协助临床避免不良事件的发生,使临床用药更加规范、合理。AIM：To provide reference for clinical rational use of drugs,clinical pharmacists carried out pharmaceutical care on a renal cell carcinoma patients with postoperative administration of sunitinib.METHODS：Adverse reactions as hypertension,yellowing of the skin and anorexia occurred on the patient taking sunitinib.Through literature review,clinical pharmacists skillfully mastered the pharmacological effects,pharmacokinetics,adverse reactions and precautions of sunitinib,then participated in the hospital treatment of the patient,developed effective treatment plan according to his renal function with the clinicians,and undertook pharmaceutical care for him.After adjusted the dosage of sunitinib,no serious adverse reactions occurred.The treatment of pleural effusion and bone metastasis was smoothly.The patient ＇s tolerance and compliance were good.RESULTS：Under the active surveillance and intervention of clinical pharmacists,the patient＆#39;s adverse reactions were controlled,clinical symptoms were improved,and he completed this course of treatment successfully.CONCLUSION：Clinical pharmacists can improve the treatment compliance of patients,avoid the occurrence of adverse events in clinical,and make more standardized,reasonable clinical medication through the pharmaceutical care and intervention in patients with collaboration of the clinician.

关 键 词：肾细胞癌 舒尼替尼 临床药师 药学监护 

分 类 号：R969[医药卫生—药理学]